MESO
Mesoblast Limited·Healthcare
14.66
1.611%(−0.24)
Close PriceLast Updated: — ET
52W L: $9.8852W H: $21.50
MESO NEWS
globenewswire.com
Apr 29
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX: MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third fiscal quarter ended March 31, 2026.
globenewswire.com
Apr 29
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the third fiscal quarter ended March 31, 2026. “We've had a busy and exciting March quarter marked by a series of major achievements.
globenewswire.com
Apr 28
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal Phase 3 clinical trial evaluating rexlemestrocel-L for the treatment of chronic low back pain (CLBP) associated with degenerative disc disease has achieved its patient recruitment target. This marks a significant milestone in Mesoblast's plans for commercialization of rexlemestrocel-L, its proprietary allogeneic stromal cell therapy targeting inflammatory processes underlying disc degeneration.
globenewswire.com
Apr 14
Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform for precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell (MSC) products. Mesoblast plans to incorporate the engineered CARs to further boost effectiveness of Mesoblast's products, with the goal of enhancing the target specificity and augmenting inherent properties of immunomodulation and tissue regeneration.
gurufocus.com
Apr 14
First Look: JPM beats, RVMD surges, NXST-TGNA paused
Stock News JPMorgan tops Q1 estimates: JPMorgan Chase (JPM) posted Q1 EPS of $5.94 on revenue of $50.54B, beating estimates on stronger fixed income trading and
defenseworld.net
Apr 12
Gregory George Acquires 1,981,890 Shares of Mesoblast (NASDAQ:MESO) Stock
Mesoblast Limited (NASDAQ: MESO - Get Free Report) Director Gregory George bought 1,981,890 shares of Mesoblast stock in a transaction that occurred on Thursday, April 9th. The stock was purchased at an average cost of $8.59 per share, with a total value of $17,024,435.10. Following the completion of the transaction, the director owned 13,586,890 shares of
